CT SB00820

Defines "pharmacogenomics" as the study of how an individual's genetic makeup affects the body's response to prescription drugs and "medically necessary" as a determination made by a treating primary care practitioner.

Requires the Commissioner of Social Services to provide Medicaid coverage for pharmacogenomics tests determined to be medically necessary, to the extent permitted under federal law.

Eliminates prior authorization requirements for medically necessary pharmacogenomics tests for persons being treated for behavioral disorders, psychiatric disorders, cardiovascular disorders, and chronic pain.

Allows the commissioner to give preference to Medicaid-enrolled laboratory providers offering discounted prices for pharmacogenomics tests.

Effective July 1, 2019, with authority for the commissioner to amend the Medicaid state plan if necessary to provide coverage for these tests.